花旗:友邦(1299.HK)新CEO上場 料業務重點轉向中國擴張
中國平安(02318.HK)首席執行官李源祥將出任友邦(01299.HK)首席執行官兼總裁,以代替明年5月底退休的黃經輝。花旗發表報告指,相信此舉將為友邦業務開啟新一頁,將集中擴張中國市場,相信李源祥可更好地與中國各省份之監管當局溝通,及招聘當地經紀,以開啟更多業務地區。
該行亦相信李源祥接任後可令友邦中分銷渠道更多元化,及提升其科技含量。另外,解決繼任人問題對股價造成的不確定因素亦消除,相信除了香港政治事件將令股價短期受壓外,其中國業務發展可長期推動股價表現。該行給予友邦目標價90港元,評級“買入”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.